PriceTargets.com logo

Artelo Biosciences - ARTL Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $5.50
  • Forecasted Upside: 388.45%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 2 Strong Buy Ratings
$1.13 As of 01/8/2025 04:57 PM ET
▼ -0.0269 (-2.33%)

This chart shows the closing price for ARTL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Artelo Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARTL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARTL

Analyst Price Target is $5.50
▲ +388.45% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Artelo Biosciences in the last 3 months. The average price target is $5.50, with a high forecast of $6.00 and a low forecast of $5.00. The average price target represents a 388.45% upside from the last price of $1.13.

This chart shows the closing price for ARTL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Buy

The current consensus among 4 polled investment analysts is to buy (strong buy) stock in Artelo Biosciences. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/18/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/16/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/14/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/13/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/12/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/10/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2025

Latest Recommendations

  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/25/2024LADENBURG THALM/SH SHUpgradeStrong-Buy
12/9/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
12/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
10/1/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
8/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
6/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00
4/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$5.00
4/3/2023LADENBURG THALM/SH SHReiterated RatingBuy$60.00
2/3/2023HC WainwrightReiterated RatingBuy$55.00
8/12/2022HC WainwrightReiterated RatingBuy$55.00
4/12/2022HC WainwrightReiterated RatingBuy$60.00
1/14/2022HC WainwrightReiterated RatingBuy$60.00
11/30/2021HC WainwrightReiterated RatingBuy$60.00
11/1/2021HC WainwrightInitiated CoverageBuy$60.00
10/8/2021Maxim GroupInitiated CoverageBuy$45.00
7/19/2021LADENBURG THALM/SH SHReiterated RatingBuy$105.00
2/12/2021LADENBURG THALM/SH SHInitiated CoverageBuy$105.00
1/7/2021Maxim GroupUpgradeHold ➝ Buy
5/13/2020Maxim GroupDowngradeBuy ➝ Hold
(Data available from 1/8/2020 forward)

News Sentiment Rating

-0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/12/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2025

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Artelo Biosciences logo
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Read More

Today's Range

Now: $1.13
Low: $1.09
High: $1.17

50 Day Range

MA: $1.10
Low: $0.95
High: $1.25

52 Week Range

Now: $1.13
Low: $0.91
High: $1.75

Volume

38,233 shs

Average Volume

30,597 shs

Market Capitalization

$3.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Artelo Biosciences?

The following Wall Street research analysts have issued stock ratings on Artelo Biosciences in the last twelve months: D. Boral Capital, EF Hutton Acquisition Co. I, HC Wainwright, and LADENBURG THALM/SH SH.
View the latest analyst ratings for ARTL.

What is the current price target for Artelo Biosciences?

0 Wall Street analysts have set twelve-month price targets for Artelo Biosciences in the last year. Their average twelve-month price target is $5.50, suggesting a possible upside of 388.5%. D. Boral Capital has the highest price target set, predicting ARTL will reach $6.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Artelo Biosciences in the next year.
View the latest price targets for ARTL.

What is the current consensus analyst rating for Artelo Biosciences?

Artelo Biosciences currently has 2 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for ARTL.

What other companies compete with Artelo Biosciences?

Other companies that are similar to Artelo Biosciences include Coeptis Therapeutics, Imunon, CervoMed, Eyenovia and Relmada Therapeutics. Learn More about companies similar to Artelo Biosciences.

How do I contact Artelo Biosciences' investor relations team?

Artelo Biosciences' physical mailing address is 888 Prospect Street Suite 210, La Jolla CA, 92037. The company's listed phone number is (858) 925-7049 and its investor relations email address is [email protected]. The official website for Artelo Biosciences is www.artelobio.com. Learn More about contacing Artelo Biosciences investor relations.